Pulmonary embolism (PE) remains a major contributor to global disease burden. Risk-adapted treatment and follow-up contributes to a favorable outcome. Age-adjusted cutoff levels increase D-dimer specificity and may decrease overuse of imaging procedures and overdiagnosis of PE. Primary systemic fibrinolysis has an unfavorable risk-benefit ratio in intermediate-risk PE; catheter-directed techniques are an option for patients with hemodynamic decompensation and high bleeding risk. New oral anticoagulant agents are effective and safe alternatives to standard anticoagulation regimens. Recent trial data do not support insertion of cava filters in patients who can receive anticoagulant treatments. Remaining areas of uncertainty include the therapeutic implications of subsegmental PE, the optimal diagnostic approach to the pregnant patient with suspected PE, and the efficacy and safety of new oral anticoagulant agents in patients with cancer. Campaigns to increase awareness combined with strategies to implement guideline recommendations will be crucial steps towards further optimizing management of acute PE. (J Am Coll Cardiol 2016;67:976-90)
management strategies for acute PE in past years, while also highlighting areas that remain to be clarified or resolved by ongoing and future research. (4) . Although a negative test safely excludes PE without further testing in these cases, the specificity of a positive D-dimer test is low and decreases steadily with age. This might result in too many positive tests and, consequently, in overuse of diagnostic imaging, particularly in the elderly.
A multicenter, prospective management study evaluated age-adjusted (age Â 10 mg/l, above 50 years) cutoff levels in a cohort of 3,346 patients with suspected PE. Patients with a normal age-adjusted D-dimer value did not undergo computed tomographic (CT) pulmonary angiography; these patients were left untreated and followed over a 3-month period. Using the age-adjusted (instead of the standard 500 mg/l) D-dimer cutoff increased the number of patients in whom PE could be excluded from 6.4% to 30% in patients aged 75 years or older, without a significant increase in the rate of VTE events during follow-up (5) .
In most countries and hospitals, CT pulmonary angiography has become the preferred imaging method for the diagnosis of acute PE in patients with that has been reported to improve diagnostic performance and reduce the number of nonconclusive tests (7) . However, the diagnostic criteria need to be standardized (8) . Moreover, head-to-head comparison of [4, 9] ). Accordingly, high-risk or massive PE refers to the presence of shock or persistent arterial hypotension as a result of overt right ventricular failure. This is clearly a life-threatening situation, in which prompt reperfusion treatment (as discussed later) is needed, along with circulatory and respiratory support in order to break the spiral of hemodynamic deterioration and to increase the chances of survival (4, 10, 11) .
More than 95% of patients with acute PE are (or appear to be) hemodynamically stable at presentation and are thus not considered to be at high risk (12) .
Within this large group, the next challenging step is to determine which patients will need hospitalization and possibly initial monitoring, and to distinguish them from those who are at truly low risk and may qualify for early discharge and outpatient treatment.
To be used as risk stratification tools for this purpose, baseline clinical parameters and prediction scores derived from them should reliably exclude severe (27) . The rate of an adverse 30-day outcome was 29% in the high-risk stratum (>4 points) of the derivation population (27) , and up to 42% in a validation cohort of 1,083 patients (28).
External validation and implementation of new prediction rules in prospective management trials are necessary steps before these can be integrated into future risk stratification algorithms. Table 1 .
ADVANCES IN ANTICOAGULATION
Post-marketing experience with these drugs in clinical practice (under "real-world" conditions) appears reassuring in the setting of stroke prevention in atrial fibrillation, and has also begun to accumulate in VTE.
In a prospective German registry of patients treated with rivaroxaban, rates of major bleeding for patients with VTE were 4.1% per year (95% CI: 2.5% to 6.4% per year), and case fatality rates were low (approximately 5% at 30 days) (37) . Importantly, available data suggest that the first reversal agent against a NOAC, the monoclonal antibody idarucizumab, which binds the thrombin inhibitor dabigatran, is effective in emergency situations (38) ; this agent is expected to obtain U.S. Food and Drug Administration approval soon. In parallel, phase 3 clinical trials are currently being conducted with andexanet, a modified recombinant form of factor Xa, which is catalytically inactive (39) and may serve as a reversal agent for rivaroxaban, apixaban, and edoxaban.
Single oral drug regimens for PE might be expected to improve (reduce) patients' perceived burden of Conversely, the proportion of a first VTE event that could be attributed to cancer was consistently around 20% in population-based studies and registries (reviewed in [77] (35, 94, 96) , but also of contemporary VKA-based anticoagulation (93), a progressive shift of anticoagulation strategies towards indefinite treatment periods after a first unprovoked PE can be anticipated, provided that it can be confirmed with real-world data that the favorable risk-to-benefit ratio of anticoagulation is maintained over the long term.
An ongoing randomized double-blind study is investigating the efficacy and safety of reduced-dose 
